A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD
NCT06329947
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
37
Enrollment
OTHER
Sponsor class
Conditions
Advanced Pancreatic Cancer
Interventions
DRUG:
Surufatinib 250mg/d qd once daily
Sponsor
Rui-hua Xu, MD, PhD